FDA Approves VABRINTY — URONOVA PHARMACEUTICALS, INC.

Uronova Pharmaceuticals announced the FDA approval of Vabrimty, a generic Leuprolide Acetate injection, which positions the company to compete directly with established manufacturers in the hormone therapy market. This clearance enables Uronova to capitalize on existing demand for the subcutaneous administration of the product, potentially boosting near-term revenue streams.